IMMUNE-MEDIATED MYOCARDITIS FOLLOWING SINGLE DOSE OF ADJUVANT ATEZOLIZUMAB: DOES BENEFIT OUTWEIGH RISK?Ashwin S. Kumar, Ana Barac, Harjit Singh et al.|Journal of the American College of Cardiology|2023Cited by 1